A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang,Sofie Claerhout,Aleix Prat,Lacey E. Dobrolecki,Ivana Petrovic,Qing Lai,Melissa D. Landis,Lisa Wiechmann,Rachel Schiff,Mario Giuliano,Helen Wong,Suzanne W. A. Fuqua,Alejandro Contreras,Carolina Gutierrez,Jian Huang,Jian Huang,Sufeng Mao,Anne Pavlick,A. Froehlich,Meng Fen Wu,Anna Tsimelzon,Susan G. Hilsenbeck,Edward S. Chen,Pavel Zuloaga,Chad A. Shaw,Mothaffar F. Rimawi,Charles M. Perou,Gordon B. Mills,Jenny C. Chang,Michael T. Lewis +29 more
Reads0
Chats0
TLDR
Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically.Abstract:
Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobese diabetic (NOD)/SCID/IL-2γ-receptor null (NSG) mice under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (∼21% and ∼19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing 25 unique patients. Most tumors yielding xenografts were “triple-negative” [estrogen receptor (ER)−progesterone receptor (PR)−HER2+; n = 19]. However, we established lines from 3 ER−PR−HER2+ tumors, one ER+PR−HER2−, one ER+PR+HER2−, and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biologic consistency with the tumor of origin, are phenotypically stable across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses as those observed clinically. Xenografts representing 12 patients, including 2 ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. Cancer Res; 73(15); 4885–97. ©2013 AACR .read more
Citations
More filters
Journal ArticleDOI
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
TL;DR: In this paper, the authors outline progress surrounding the molecular mechanisms involved in breast cancer brain metastasis as well as experimental methods and research models to better understand the process and provide an overview of current therapies and highlighting innovative research towards developing novel efficacious targeted therapies.
Journal ArticleDOI
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Maria Rivera,Iduna Fichtner,Annika Wulf-Goldenberg,Christine Sers,Johannes Merk,Giannino Patone,Keziban M. Alp,Tamara Kanashova,Philipp Mertins,Jens Hoffmann,Ulrike Stein,Wolfgang Walther +11 more
TL;DR: Patient-derived xenograft (PDX) tumor models represent a valuable platform for identifying new biomarkers and novel targets, to evaluate therapy response and resistance mechanisms and demonstrate that PDX models provide a multitude of possibilities to identify and validate biomarkers, signaling pathways and resistance mechanism for clinically relevant improvement in cancer therapy.
Journal ArticleDOI
Bioengineering Models for Breast Cancer Research.
TL;DR: Recent advances in the use of three-dimensional cell culture models to study various aspects of BC disease in vitro are described and the emerging area of studying BC dormancy using these models is reviewed.
Journal ArticleDOI
Advances in Precision Medicine: Tailoring Individualized Therapies.
TL;DR: Advances in precision medicine presented at the Irish Association for Cancer Research Annual Meeting are discussed, highlighting examples where personalized medicine approaches have led to precision discovery in individual tumors, informing customized treatment programs.
Journal ArticleDOI
Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.
Qilai Long,Tzu-yin Lin,Yee Huang,Xiaocen Li,Ai-Hong Ma,Hongyong Zhang,Randy P. Carney,Susan D. Airhart,Kit S. Lam,Ralph W deVere White,Chong-Xian Pan,Yuanpei Li +11 more
TL;DR: A novel multifunctional nanoporphyrin platform loaded with an HSP90 inhibitor 17AAG (NP-AAG) for use as a multi-modality therapy against bladder cancer was evaluated and could dramatically improve management for bladder cancers with minimal toxicity.
References
More filters
Journal ArticleDOI
Prospective identification of tumorigenic breast cancer cells
Muhammad Al-Hajj,Max S. Wicha,Adalberto Benito-Hernandez,Sean J. Morrison,Sean J. Morrison,Michael F. Clarke +5 more
TL;DR: The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival and strategies designed to target this population may lead to more effective therapies.
Journal ArticleDOI
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker,Michael Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,Christiane Fauron,Xiaping He,Zhiyuan Hu,John Quackenbush,Inge J. Stijleman,Juan P. Palazzo,James Stephen Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard +19 more
TL;DR: D diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer.
Journal ArticleDOI
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub,Ajeeta B. Dash,Annie P. Vo,Andrew J. Sullivan,Mary W. Brooks,George W. Bell,Andrea L. Richardson,Kornelia Polyak,Ross Tubo,Robert A. Weinberg +9 more
TL;DR: It is demonstrated that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft.
Journal ArticleDOI
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat,Joel S. Parker,Olga Karginova,Cheng Fan,Chad A. Livasy,Jason I. Herschkowitz,Xiaping He,Charles M. Perou +7 more
TL;DR: It is confirmed that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.
Journal ArticleDOI
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu,Cheng Fan,Daniel S. Oh,James Stephen Marron,Xiaping He,Bahjat F. Qaqish,Chad A. Livasy,Lisa A. Carey,Evangeline R Reynolds,Lynn G. Dressler,Andrew B. Nobel,Joel S. Parker,Matthew G. Ewend,Lynda R. Sawyer,Junyuan Wu,Yudong Liu,Rita Nanda,Maria Tretiakova,Alejandra Ruiz Orrico,Donna Dreher,Juan P. Palazzo,Laurent Perreard,Edward W. Nelson,Mary C. Mone,Heidi Theil Hansen,Michael Mullins,John Quackenbush,Matthew J. Ellis,Olufunmilayo I. Olopade,Philip S. Bernard,Charles M. Perou +30 more
TL;DR: This study validates the "breast tumor intrinsic" subtype classification as an objective means of tumor classification that should be translated into a clinical assay for further retrospective and prospective validation.
Related Papers (5)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Andrea Bertotti,Giorgia Migliardi,Francesco Galimi,Francesco Sassi,Davide Torti,Claudio Isella,Davide Corà,Federica Di Nicolantonio,Michela Buscarino,Consalvo Petti,Dario Ribero,Nadia Russolillo,Andrea Muratore,Paolo Massucco,Alberto Pisacane,Luca Molinaro,Emanuele Valtorta,Andrea Sartore-Bianchi,Mauro Risio,Lorenzo Capussotti,Marcello Gambacorta,Salvatore Siena,Enzo Medico,Anna Sapino,Silvia Marsoni,Paolo M. Comoglio,Alberto Bardelli,Livio Trusolino +27 more